Assessment of the reporting quality of double-blind RCTs for ischemic stroke based on the CONSORT statement.


Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 08 2020
Historique:
received: 22 04 2020
revised: 10 05 2020
accepted: 18 05 2020
pubmed: 4 6 2020
medline: 15 5 2021
entrez: 4 6 2020
Statut: ppublish

Résumé

It is critical that Randomized Controlled Trials(RCTs) present complete and transparent reporting. The present study aims to determine the reporting quality of double-blind RCTs for medicinal interventions in patients with ischemic stroke, based on the 2010 CONSORT-statement. MEDLINE was comprehensively searched. The CONSORT period was demarcated between 2000 and 2019, while compliance ≥75 was defined as good-adequate. Possible determinants were univariately and multivariately examined for associations. Overall, 197 articles were considered eligible, 143 published after and 54 before 2000. CONSORT compliance was 68.11% ± 11.56% (standard deviation) and 55.65% ± 11.57% respectively. Among retrieved articles 56/143(39.16%) and 1/54(1.85%) were rated as of good reporting quality correspondingly [p < .001, OR = 34.115, 95%CI = (4.586, 253.762)]. McNemar's test was indicative of consistency regarding the adequately/inadequately reported items before and after the 2010 CONSORT-revision (p = 1.00). Univariate analysis revealed two significant associations with the reporting quality: high impact factor(IF) [high vs. moderate; p = .007, OR = 3.521, 95%CI = (1.396, 8.879), high vs. low; p < .001, OR = 7.583, 95%CI = (3.063, 18.762), moderate vs. low; p = .078, OR = 2.154, 95%CI = (0.911, 5.093)] and sample size [p < .001, OR = 4.297, 95%CI = (2.081, 8.874)]. Publication period (p = .742) and funding (p = .280) were not significantly associated. Multivariate analysis attenuated the impact of sample size providing insignificant results, whereas the effect of high IF remained significant [moderate vs. high; p = .029, OR = 0.337, 95%CI = (0.127, 0.895), low vs. high; p = .012, OR = 0.199, 95%CI = (0.057, 0.699)]. An exploratory analysis demonstrated significant, weak to moderate, positive linear correlation between reporting quality and IF [Pearson's r = 0.418, p < .001]. Adherence to the CONSORT-statement needs to be further endorsed and incorporated in every journal's instructions-to-authors.

Sections du résumé

BACKGROUND-PURPOSE
It is critical that Randomized Controlled Trials(RCTs) present complete and transparent reporting. The present study aims to determine the reporting quality of double-blind RCTs for medicinal interventions in patients with ischemic stroke, based on the 2010 CONSORT-statement.
METHODOLOGY
MEDLINE was comprehensively searched. The CONSORT period was demarcated between 2000 and 2019, while compliance ≥75 was defined as good-adequate. Possible determinants were univariately and multivariately examined for associations.
RESULTS
Overall, 197 articles were considered eligible, 143 published after and 54 before 2000. CONSORT compliance was 68.11% ± 11.56% (standard deviation) and 55.65% ± 11.57% respectively. Among retrieved articles 56/143(39.16%) and 1/54(1.85%) were rated as of good reporting quality correspondingly [p < .001, OR = 34.115, 95%CI = (4.586, 253.762)]. McNemar's test was indicative of consistency regarding the adequately/inadequately reported items before and after the 2010 CONSORT-revision (p = 1.00). Univariate analysis revealed two significant associations with the reporting quality: high impact factor(IF) [high vs. moderate; p = .007, OR = 3.521, 95%CI = (1.396, 8.879), high vs. low; p < .001, OR = 7.583, 95%CI = (3.063, 18.762), moderate vs. low; p = .078, OR = 2.154, 95%CI = (0.911, 5.093)] and sample size [p < .001, OR = 4.297, 95%CI = (2.081, 8.874)]. Publication period (p = .742) and funding (p = .280) were not significantly associated. Multivariate analysis attenuated the impact of sample size providing insignificant results, whereas the effect of high IF remained significant [moderate vs. high; p = .029, OR = 0.337, 95%CI = (0.127, 0.895), low vs. high; p = .012, OR = 0.199, 95%CI = (0.057, 0.699)]. An exploratory analysis demonstrated significant, weak to moderate, positive linear correlation between reporting quality and IF [Pearson's r = 0.418, p < .001].
CONCLUSIONS
Adherence to the CONSORT-statement needs to be further endorsed and incorporated in every journal's instructions-to-authors.

Identifiants

pubmed: 32492609
pii: S0022-510X(20)30275-6
doi: 10.1016/j.jns.2020.116938
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116938

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Michalis Kodounis (M)

Department of Neurology, University Hospital of Larissa, School of Medicine, University of Thessaly, Larissa, Greece.

Ioannis N Liampas (IN)

Department of Neurology, University Hospital of Larissa, School of Medicine, University of Thessaly, Larissa, Greece. Electronic address: liampasioannes@gmail.com.

Theodoros S Constantinidis (TS)

Department of Neurology, University Hospital of Larissa, School of Medicine, University of Thessaly, Larissa, Greece.

Vasileios Siokas (V)

Department of Neurology, University Hospital of Larissa, School of Medicine, University of Thessaly, Larissa, Greece.

Alexios-Fotios A Mentis (AA)

Department of Microbiology, University Hospital of Larissa, School of Medicine, University of Thessaly, Larissa, Greece; Public Health Laboratories, Hellenic Pasteur Institute, Athens, Greece.

Athina-Maria Aloizou (AM)

Department of Neurology, University Hospital of Larissa, School of Medicine, University of Thessaly, Larissa, Greece.

Georgia Xiromerisiou (G)

Department of Neurology, University Hospital of Larissa, School of Medicine, University of Thessaly, Larissa, Greece.

Elias Zintzaras (E)

Department of Biomathematics, School of Medicine, University of Thessaly, Larissa, Greece; Center for Clinical Evidence Synthesis, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA.

Georgios M Hadjigeorgiou (GM)

Department of Neurology, University Hospital of Larissa, School of Medicine, University of Thessaly, Larissa, Greece; Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus.

Efthimios Dardiotis (E)

Department of Neurology, University Hospital of Larissa, School of Medicine, University of Thessaly, Larissa, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH